Multiple Sclerosis

FDA approves Biogen and Alkermes’ multiple sclerosis drug

Read more

Novartis MS drug cuts relapse rate by half compared to Sanofi medicine

Read more

Novartis’s Sandoz licenses proposed multiple sclerosis biosimilar

Read more

Space study seeks treatments for Parkinson’s, multiple sclerosis

Read more

Multiple sclerosis treatment market value to reach $20 bn by 2024

Read more

Merck plans registration of Cladribine tablets in Europe

Read more

Genzyme’s Lemtrada approved by the FDA

Read more